Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026

On March 18, 2026 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, reported that updated pre-clinical data for MDNA113, its first-in-class PD-1 x IL-2 bifunctional superkine advancing toward an IND submission in H2 2026, will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17–22 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentation are as follows:

Title: MDNA113 is a masked conditionally activated tumor-targeted anti-PD1-IL-2SK with superior safety and therapeutic properties.
Session Title: Monoclonal Antibodies and Antibody-Cytokine Platforms
Session Date and Time: Tuesday, April 21st, 2026; 9:00 AM – 12:00 PM
Location: Poster Section 9
Poster Board Number: 13
Abstract Number: 4342

Following the presentation, a copy will be available on the "Scientific Presentations" page of Medicenna’s website.

About MDNA113:

MDNA113 is a novel, first-in-class tumor-targeted and tumor-activated bi-functional anti-PD1-IL-2 Superkine with exceptionally high affinity for IL-13Rα2 without binding to the functional IL-13R⍺1. IL-13Rα2 is overexpressed in a wide range of solid tumors, including cold tumors with minimal to no expression in normal tissues. IL-13Rα2 expressing tumors also have abundant matrix metalloprotease in the tumor microenvironment that may efficiently activate MDNA113. IL-13Rα2 expression is associated with poor clinical outcome in multiple tumor types including prostate, pancreatic, ovarian, liver, breast and brain cancer, with an annual world-wide incidence of over 2 million.

(Press release, Medicenna Therapeutics, MAR 18, 2026, View Source [SID1234663731])